Accessibility Menu
Dss logo

Dss(NYSEMKT) DSS

Market Cap$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-98%
1 Year-55%
1 Month+2%
$0.55
+1.99%
+0.01Today
Dss last closing stock price
MetricPriceDate
Last closeUSD 0.552026-09-01
Dss stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.41%USD 0.542026-08-25
1 month+2.14%USD 0.542026-07-31
3 month+16.1%USD 0.472026-06-03
Year to date-40.94%USD 0.932025-12-31
1 year-55.45%USD 1.232025-08-29
3 year-85.78%USD 3.852023-09-01
5 year-97.66%USD 23.392021-09-02
Since inception-100%USD 15,749.392007-12-03

Dss Financials at a Glance

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.45M

Net Income (TTM)

-$27.65M

EPS (TTM)

-$2.95

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$0.55

Volume

102

Open

$0.53

Previous Close

$0.55

Daily Range

$0.53 - $0.59

52-Week Range

$0.36 - $1.86

Estimated Earnings Date

Oct 26, 2026

DSS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dss

DSS makes packaging for medicines and foods, helping products stay safe and secure. Its biotech division develops health solutions for disease prevention and treatment. DSS also offers lending and investment services for businesses and investors.

Unpacking the Offerings: DSS’s Main Products

  • Product Packaging (87.5% of revenue): Custom cartons, mailers, and secure printing for pharmaceuticals, foods, and consumer goods.
  • Securities & Investment Management (12.2%): Broker-dealer services, investment advisory, and real estate investment trusts for healthcare properties.
  • Commercial Lending (0.2%): Business loans, equipment financing, and loan servicing for small and mid-sized companies.
  • Biotechnology (0.2%): Research and development of health products, including drug discovery and disease prevention technologies.

Growth Moves: DSS’s Expansion Playbook

  • Acquired Premier Packaging Corporation to expand packaging.
  • Launched Impact BioMedical prior to its IPO in 2024.
  • Sold non-core assets, including Celios air purification (2025) and Plano, TX facility (2025).
  • Expanded Sentinel Brokers with new trading approvals in 2025.
  • Focused on acquiring equity positions in financial companies operating in the United States and Asia.

What Makes DSS Stand Out

DSS operates across packaging, biotech, lending, and investment, reducing reliance on one sector. Its decentralized model aims to share subsidiary IPO gains with shareholders. The company invests in patents and sustainability, focusing on innovation and operational upgrades.

Five Things You Need to Know

  • Revenue was $20.76 million in 2025, up 9% from 2024.
  • Product packaging made up approximately 87% of 2025 revenue.
  • Operating loss was $(14.43) million in 2025, compared to $(42.60) million in 2024.
  • Cash at year-end 2025 was $6.21 million, down from $11.43 million in 2024.
  • One customer accounted for 29% of total revenue in 2025.

Bottom Line

DSS has evolved into a diversified holding company with a focus on packaging, biotech, and financial services. Its broad approach and ongoing restructuring reflect efforts to adapt and manage risk.

AI Generated • Apr 16, 2026

Industry

Commercial Services and Supplies

Employees

102

CEO

Jason T. Grady, MBA

Headquarters

West Henrietta, NY 14586, US

DSS Financials

Key Financial Metrics (TTM)

Gross Margin

-20.80%

Operating Margin

-89.72%

Net Income Margin

-149.84%

Return on Equity

-675.92%

Return on Capital

-34.18%

Return on Assets

-40.46%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.04M

Volume

102

Avg. Volume

1.41M

Financials (TTM)

Gross Profit

-$3.84M

Operating Income

-$16.56M

EBITDA

-$27.61M

Operating Cash Flow

-$11.54M

Capital Expenditure

-$338.00K

Free Cash Flow

-$11.88M

Cash & ST Invst.

$5.16M

Total Debt

$43.14M

Dss Performance Analysis

Dss annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,307,000133.3%
20232023-12-31USD 25,933,000-45.2%
20242024-12-31USD 19,097,000-26.4%
20252025-12-31USD 20,757,0008.7%
Dss sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.9%
Q42025-12-31-35.4%
Q12026-03-314.9%
Q22026-06-30-16.8%
Dss annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.72-22.1%
20232023-12-31USD -8.67-19.2%
20242024-12-31USD -6.63-23.5%
20252025-12-31USD -2.66-59.9%
Dss sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.2%
Q42025-12-31-548.0%
Q12026-03-3163.0%
Q22026-06-3020.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.60M

-31.8%

Gross Profit

-$915.00K

-327.6%

Gross Margin

-25.39%

N/A

Market Cap

$5.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$53.95K

N/A

Employees

102

N/A

Net Income

-$4.79M

-122.5%

EBITDA

-$4.95M

-153.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.16M

-58.3%

Total Debt

$43.14M

-23.5%

Accounts Receivable

$1.77M

-41.0%

Inventory

$1.98M

-22.2%

Long Term Debt

$10.66M

-12.5%

Short Term Debt

$32.48M

-26.5%

Return on Assets

-40.46%

N/A

Return on Invested Capital

-86.65%

N/A

Free Cash Flow

-$1.87M

-194.6%

Operating Cash Flow

-$1.85M

-189.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATERAterian, Inc.
$0.45+12.50%
MRMMEDIROM Healthcare Technologies Inc.
$0.93-1.05%
LOBOLobo Technologies Ltd.
$0.58-0.02%
FLYEFly-E Group, Inc. Common Stock
$2.20+61.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$52.22+0.07%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$105.91-0.06%
IBITiShares Bitcoin Trust
$43.76-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$39.97+0.04%

Questions About DSS

What is the current price of Dss?

Dss is trading at $0.55 per share.

What is the 52-week range for Dss?

Over the past 52 weeks, Dss has traded between $0.36 and $1.86.

How much debt does Dss have?

As of the most recent reporting period, Dss reported total debt of $43.14M.

How much cash does Dss have on hand?

Dss reported $4.07M in cash and cash equivalents in its most recent financial results.

What is Dss’s dividend yield?

Dss does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.